|
The following stocks are the leading risers and fallers on AIM on Wednesday. ---------- AIM - WINNERS ---------- Faron Pharmaceuticals Ltd, up 13% at 220.00 pence, 12-month range 140.00p-270.00p. The Turku, Finland-based developer of cancer immunotherapies developer reports an increase in the complete remission rate in patients with frontline or treatment-naive high-risk myelodysplastic syndrome, in data from its phase 1/2 Bexmab trial, which compared the combination therapy of bexmarilimab and the current standard-of-care azacitidine. The CR rate increases to 43%, or 9 out of 21 patients, an improvement on the 28% rate seen in earlier data and more than double the 16% to 17% rate seen in patients treated with azacitidine alone. ‘The continued maturation of the Bexmab data demonstrates bexmarilimab’s profound impact as a disease-modifying agent,’ says Chief Medical Officer Petri Bono. ‘Seeing the CR rate strengthen over time to 43%, which complements the robust 50% [composite] CR we have already reported, is very encouraging. It provides us with two compelling and clinically meaningful data sets for discussion with the [US Food & Drug Administration] and gives us confidence in proposing a randomised registrational trial designed for accelerated approval with either CR or cCR as the primary endpoint.’ ---------- CT Automotive Group PLC, up 11% at 36.51p, 12-month range 21.00p-61.02p. The Portsmouth, England-based designer, developer and supplier of interior components to the automotive industry says it remains on track to meet full-year market expectations, citing a company-compiled consensus for $122.0 million in revenue and adjusted pretax profit of $10.5 million. This would be up 1.9% and 21% respectively from $119.7 million and $8.7 million in 2024. For the first half that ended June 30, the firm expects to post revenue of $54.2 million, down 10% from $60.5 million a year before. This reflects customer program launch timing adjustments and inventory run down, CT Automotive explains, adding that revenue is anticipated to ‘normalise’ during the second half. The firm says it secured a total of eight new contracts during the six-month period, worth around $37 million a year. The company is investing $3.4 million during 2025 into its Mexico facility, citing ‘success’ at the location despite market uncertainty introduced by US tariffs. ‘Across the group, we continue to deliver efficient, low-cost manufacturing solutions through our three global production centres,’ says CT Automotive. ‘The new contract wins demonstrate customer confidence in CT Automotive and provide enhanced revenue visibility for FY25, FY26 and beyond. Combined with continued investment in innovation, and a focus on operational efficiency, the board remains confident in CT Automotive’s outlook and growth prospects.’ ---------- AIM - LOSERS ---------- ImmuPharma PLC, down 28% at 1.49p, 12-month range 0.85p-7.40p. The London-based specialist drug discovery and development company says its pretax loss widened to £1.9 million in the six months that ended June 30, from a £594,767 million loss a year prior. This is primarily due to research and development expenses rising 46% to £690,021 from £473,521, and administrative expenses nearly doubling to £490,676 from £258,023. ‘At an operational level, we have maintained a strong focus on rigorous cost control measures and strategic outsourcing to minimise fixed overheads, while advancing our research and development efforts,’ says Chief Executive Officer & Chair Tim McCarthy. ‘These initiatives are aligned with our preparation for upcoming patent filings this year. Furthermore, we strengthened the balance sheet and extended our cash runway through the successful completion of an oversubscribed placing in February 2025.’ The firm adds it remains focused on bringing its two key late-stage clinical assets, P140 for systemic lupus erythematosus and chronic inflammatory demyelinating polyneuropathy, closer to the market, and on securing further partnership deals for P140 together with its earlier stage assets. ---------- Copyright 2025 Alliance News Ltd. All Rights Reserved.
|
